Based on this evidence, platinum-based chemotherapy plus PD-1/PD-L1 inhibitor is strongly recommended in patients with PS 0–1, whose tumor is positive for PD-L1 ≥ 50%, and who do not have EGFR mutation or ALK rearrangement. The gene discussed is ALK; the disease is neoplasm.